scholarly journals Prognosis for Metastatic Colorectal Cancer Patients Achieving Complete Response After Systemic Chemotherapy

2021 ◽  
Author(s):  
Takahiro Manabe ◽  
Yasumasa Takii ◽  
Hidehito Oyanagi ◽  
Hitoshi Nogami ◽  
Satoshi Maruyama
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Disease Progression ◽  
Systemic Chemotherapy ◽  
Negative Impact ◽  
Treatment Strategies ◽  
Progression Free Survival ◽  
Complete Response ◽  
Maintenance Chemotherapy ◽  
Colorectal Cancer Patients

Abstract Background: Despite marked recent advances in chemotherapy, few reports have focused on the prognosis for patients with metastatic colorectal cancer (mCRC) achieving complete response (CR) after systemic chemotherapy. This study investigated the clinical course of mCRC patients achieving CR and evaluated the role of CR in chemotherapy.Methods: This retrospective study searched a prospectively maintained database at the author’s institute to identify medical records for mCRC patients achieving CR after systematic chemotherapy from January 2007 to March 2020.Results: The search yielded 23 patients with confirmed CR to systemic chemotherapy. Median time to CR from treatment initiation was 6.8 months. Maintenance chemotherapy was continued for 22 of 23 patients. Median duration of maintenance chemotherapy was 11.1 months. Disease progression occurred for 17 (73.9%) patients at a median 48.1-month follow-up. Median progression-free survival was 26.6 months. Median overall survival was 91.7 months.Conclusions: Patients with CR to chemotherapy had a high probability of disease progression, but a relatively long-term prognosis. Treatment strategies after achievement of CR should be based an understanding of the high potential that tumor cells will remain. Use of maintenance chemotherapy after achievement of CR is still unclear, the recent data do not demonstrate a negative impact for continuing maintenance chemotherapy after CR.

scholarly journals The Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitor in ≥3 line MSS Metastatic Colorectal Cancer Patients

2021 ◽  
Author(s):  
Xiangyi Wang ◽  
li lin ◽  
jun liang
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Progression Free Survival ◽  
Complete Response ◽  
Efficacy And Safety ◽  
Once Daily ◽  
Grade 5 ◽  
Grade 3 ◽  
Vegfr Inhibitor ◽  
Colorectal Cancer Patients

Abstract Purpose: Based on the suggestion of REGONIVO study, we reviewed the data of 26 MSS mCRC patients to elaborate the efficacy and safety of fruquintinib (a VEGFR inhibitor) plus PD-1 inhibitor and explore the potential predictors for survival in 3+ line microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients.Patients and methods: This retrospective study enrolled 26 MSS mCRC patients who progressed after at least 2 lines of systematic chemotherapy but didn’t receive PD-1 inhibitors. Fruquintinib of 3mg was administered once daily with 21 days on/7 days off plus PD-1 inhibitor 200mg every 3 weeks until intolerable toxicity or disease progression. Results: Median overall survival (mOS) was 6.1m (ranged 1.8m-NR 95%CI: 2.60-9.60); median progression free survival (mPFS) was 2.3m (ranged 1.5m-NR 95%CI: 0.93-3.67). There was one complete response (CR) and no partial response (PR). Stable disease was observed in 11 patients (42%) and progression disease (PD) was observed in 14 patients (54%). The object response rate (ORR) was 4% (1/26) and disease control rate (DCR) was 46 %( 12/26). Grade ≥3 AEs were observed in 5 patients (19.2%). Grade 5 AEs (immune related encephalitis and cardiotoxicity) were observed in 2 patients. Additionally, there was a significant correlation between NLR < 3.06 and longer survival (P=0.000) for MSS mCRC patients treated with fruquintinib plus PD-1 inhibitor. Conclusions: Fruquintinib plus PD-1 inhibitor may be a choice for 3+ line MSS mCRC patients，especially with pretreatment NLR<3.06.

scholarly journals EZH2 Expression and its Correlation with Clinicopathological Features in Patients with Colorectal Carcinoma

2016 ◽  
Vol 11 (1) ◽  
pp. 287-292
Author(s):  
Xiao-yang Liu ◽  
Hua Liu ◽  
Lin Gu ◽  
Hai-lun Zheng
Keyword(s):  
Colorectal Cancer ◽  
Colorectal Carcinoma ◽  
Disease Progression ◽  
Western Blotting ◽  
Progression Free Survival ◽  
Clinicopathological Features ◽  
Tumor Biomarker ◽  
Ezh2 Expression ◽  
Significant Difference ◽  
Colorectal Cancer Patients

AbstractObjectiveTo explore the correlation between the enhancer of zeste homolog 2 (EZH2) expression and clinicopathological features in colorectal cancer patients.MethodsA total of sixty-six patients with colorectal carcinoma were admitted to our general surgery department from January 2011 to December 2014. The EZH2 expression levels in the cancer tissues (CTs) from the 66 patients with colorectal cancer and those in distant normal colorectal tissues from 30 cases were examined through immunohistochemistry and western blotting assays. The relationship between the expression of EZH2 and the clinicopathological features and prognosis of the patients was analyzed.ResultsEZH2 in colorectal carcinoma tissues is granularly brown, predominantly expressed and diffused in the nuclei of tumor cells. Positive rates of EZH2 in intestinal CTs and in distant normal intestinal tissues are 62.12% (41/66) and 6.67% (2/30), respectively with significant difference (P < 0.05). Western blotting also confirmed its elevated expression in colorectal CTs. EZH2-positive expression in CTs was related to degree of differentiation, Duke staging, and tumor size (P < 0.05) but was unrelated to the patient’s gender, age or tumor site (P = 0.05). The 3-year progression-free survival (PFS) rates of the EZH2-positive group and the EZH2-negative group were 43.8% and 67.5%, respectively. The risk of disease progression of the EZH2-positive patients in the follow-up period was significantly higher than that of the EZH2-negative patients (HR = 2.49, 95% CI = 1.04–4.80, P < 0.05).ConclusionEZH2 is closely related to colorectal carcinoma development and disease progression, and thus could be used as a tumor biomarker that may indicate prognosis.

scholarly journals Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable

ESMO Open ◽  
2019 ◽  
Vol 4 (2) ◽  
pp. e000496
Author(s):  
Elena Ongaro ◽  
Chiara Cremolini ◽  
Daniele Rossini ◽  
Francesca Corti ◽  
Filippo Pagani ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Metastatic Colorectal Cancer ◽  
Disease Progression ◽  
Progression Free Survival ◽  
Extrahepatic Disease ◽  
Nodal Involvement ◽  
Liver Resections ◽  
Multicentre Cohort Study ◽  
Molecular Determinants

BackgroundNo tools to predict the probability of extrahepatic disease progression (ePD) of initially unresectable, liver-limited metastatic colorectal cancer (mCRC) are currently available. To estimate the likelihood to develop ePD and to identify clinical and molecular factors that could predict extrahepatic progression-free survival (ePFS), we conducted an observational, retrospective, multicentre cohort study.MethodsWe retrospectively identified a cohort of 225 patients with initially unresectable liver-limited disease (LLD), treated from January 2004 to December 2017 with first-line doublets or triplet plus a biological agent at two Italian institutions.Results173 (77%) patients experienced ePD which occurred within 1, 2 or 3 years from the diagnosis of mCRC in 15%, 49% and 66% of patients, respectively. Globally, 164 (73%) patients underwent a liver resection at some point of their disease history, and 54 (33%) of them underwent a subsequent locoregional treatment. Age > 70 years, locoregional nodal involvement at diagnosis of colorectal cancer and ≥4 liver metastases were significantly associated with higher risk of ePD while liver resections were associated with reduced risk of ePD. In the multivariable model, number of liver metastases (subdistribution HR, SHR 1.63, 95% CI 1.12 to 2.36; p = 0.01) and liver resections (SHR 0.43, 95% CI 0.29 to 0.63; p = 0.001) were still associated with ePD. Number of liver metastases < 4, no nodal involvement at diagnosis and liver resections were also associated with prolonged ePFS.ConclusionsThe identified clinical factors could help physicians in personalising the intensity and aggressiveness of liver-directed treatments in patients with mCRC with initially unresectable LLD.

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

2016 ◽  
Vol 55 (11) ◽  
pp. 1381-1394 ◽  
Author(s):  
Morgane Caulet ◽  
Thierry Lecomte ◽  
Olivier Bouché ◽  
Jérôme Rollin ◽  
Valérie Gouilleux-Gruart ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

scholarly journals Metastatic colorectal cancer patients who achieved long progression-free survival by regorafenib or TAS-102 therapy

2016 ◽  
Vol 27 ◽  
pp. vii78
Author(s):  
Yosuke Kito ◽  
Satoshi Hamauchi ◽  
Kentaro Yamazaki ◽  
Azusa Komori ◽  
Toshiki Masuishi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document